Table 9 (abstract P445). See text for description
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three
Demographics | |
- · Gender (M:F) | 8:5 |
- · Mean age of onset | 5.5 years (range 1.5 to 11 years) |
- · Follow up duration | 4.6 years |
Clinical Symptoms at presentation | |
- · Cough | (n = 9) 70% |
- · Dyspnea | (n = 13) 100% |
- · Anemia | (n = 13) 100% |
- · Hemoptysis | (n = 5) 35% |
- · CXR infiltrates | (n = 13) 100% |
Associated SLE Clinical features | |
- · Hematological | (n = 7) 54% |
- · Nephritis | (n = 11) 85% |
- · Arthritis | (n = 11) 85% |
- · Mucocutanous | (n = 12) 92% |
- · Serositis | (n = 7) 54% |
- · Neuropsychiatric | (n = 5)35% |
Treatment: | |
- · IVM | (n = 13) 100% |
- · CYC | (n = 9) 70% |
- · MMF | (n = 7) 54% |
- · IVIG | (n = 9) 70% |
- · Plasmapharesis | (n = 6) 46% |
- · Mechanical ventilation | (n = 7) 54% |
Outcome: | |
- · Acute DAH outcome | |
Death / Survival | (n = 1) 7% |
- · Long term SLE outcome | (n = 11) |
Remission | (n = 7) 64% |
Minimal disease activity | (n = 2)18% |
Lost to follow up | (n = 2) 15% |